About Duchenne

The Duchenne gene is found on the X-chromosome; therefore, it affects mostly males. In rare cases, it also affects females. It affects approximately 1 in every 5,000 live male births. There are approximately 15,000 patients diagnosed with Duchenne alive today in the United States.

Duchenne has no cure.

Duchenne is a progressive neuromuscular disorder that causes a loss of motor, pulmonary, and cardiac function. It is caused by a mutation in the gene that encodes for dystrophin, a lubricating protein supports muscle fiber strength. When dystrophin is missing in the body, muscle cells are easily damaged, which causes progressive muscle weakness in the entire body.

Children with Duchenne are born seemingly healthy and decline over time, typically losing their ability to walk around the age of 12 and succumbing to the disease in their early to mid-twenties.

Duchenne can be passed from parent to child, but approximately 35% of cases occur because of a random spontaneous mutation. In other words, it can affect anyone.

To learn about FDA approved drugs for Duchenne muscular dystrophy, please visit our Treatment and Care page.

For more information on Duchenne, or to learn how to support Jett Foundation’s mission of empowering individuals and families that are impacted by Duchenne, please explore our website or contact [email protected].

Diagnosis

We have gathered helpful resources and information for those on a Duchenne journey, in both its highs and lows.

Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet.

Treatment & Care

Read more about FDA approved Duchenne treatments.

Latest Duchenne News

October 7, 2026
At the end of September, Satellos Biosciences announced that enrollment is complete for BASECAMP, a Phase 2 clinical trial evaluating forazapadin, a drug candidate designed to support muscle repair and...
September 29, 2026
Today, Secretome Therapeutics announced that its Phase 2 clinical study, THRIVE-2, has opened for enrollment at participating clinical sites across the United States. The study will evaluate the safety and...
September 18, 2026
On September 8, 2026, Sarepta Therapeutics announced the recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Each recipient will receive a scholarship of up to...